A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

Charité University Medicine Berlin

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Small Cell Lung Cancer

Treatments: Drug: Carboplatin plus Irinotecan vs Carboplatin plus Etoposide

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00168896

Haema CBF SCLC UK/AS 01

Details and patient eligibility

About

Comparison of two combination chemotherapies in the treatment of patients with SLCL

Full description

Comparison of two combination chemotherapies in the treatment of patients with SLCL

The combination chemotherapies for this study are Carboplatin plus Irinotecan versus Carboplatin plus Etoposide.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• cytological or histological proven SCLC Stage I or II at 1st diagnosis
• no prior chemotherapy
• measurable tumor disease
• karnofsky performance 70

Exclusion criteria

• second malignancy ( except basal cell carcinoma, CA in situ Cervix uteri)
• NYHA III
• chronic diarrhea, obstructive bowel syndrome

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)